Institute for Cancer Research
Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.
The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.
Scientific production - Institute for Cancer Research
The Institute Seminar on Wednesday October 22nd will ble held by Erik Boye, department head at the Department of Cell Biology.
Title of his talk: "TRANSLATION AND STRESS. Serendipity, sloppiness and sensation".
Time and place: 12 - 13 in the Auditorium, New Research Building, Montebello.
The Norwegian Cancer Society (NCS) provides approximately 25 per cent of all direct funding for cancer research in Norway, thus contributing to promoting a research environment of top international standard in the country. The research section of the NCS writes popular scientific articles about scientists supported by the society.
In October - the month of the pink ribbon breast cancer awareness campaign - the NCS have published an article about professor Vessela N. Kristensen from the Department of Genetics at the Institute for Cancer Research. Kristensen's "Cancer Genome Variation" group is working on projects related to how genetic variation affects occurrence of somatic alterations, gene expression patterns and genome wide copy number alterations in human breast and ovarian tumors.
The Norwegian Inflammation Network (NORIN) is holding a seminar on Wednesday, 29 October entitled “Sufficient options to treat inflammation? Looking at the pipeline of the pharmaceutical industry.”
Register by October 24th.
Important findings from Department of Genetics published in Genome Biology and highlighted in Biome magazine
Scientists from Department of Genetics contribute to the special issue of Genome Biology (journal IF 10,5) dedicated to cancer heterogeneity and progression.
Inga H. Rye supervised by Hege Russnes developed with a group in Cambridge a software for automatized analyses of fluorescence, FISH and IFISH images to estimate both copy number variation and phenotypic traits. The software, GoIFISH, can also recognize different types of cells and visualize intra-tumor heterogeneity.
Thomas Fleischer, supervised by Vessela Kristensen from the group of Cancer Genome variation discovered an epigenetic signature of breast cancer progression with prognostic significance. This work was highlighted in the Biome magazine, which showcases some of the most interesting research publications from across BMC journals.
The recently launched Oslo University Hospital research blog is the first site of this kind among Norwegian health care institutions. In the first contribution - entitled "Health research in great request" director of research, innovation and education Erlend B. Smeland writes about how the blog will act as a platform for communicating discoveries in medical sciences in a popularised form, as well as serving as a vehicle for the hospital to stay in touch with the community. It will also be used as a channel for voicing the views of the hospital in debates concerning research policies.
New contributions will appear on the blog every other week. At first, the heads of research at the various divisions will write in turn. Ingrid Melle from the Division of Mental Health and Addiction has kicked it off by writing about how mental illnesses may harm the body. The blog is in Norwegian.
The K.G. Jebsen Colorectal Cancer Research Centre was recently officially opened by the chair of the Jebsen Foundation’s board of directors, Hans Peter Jebsen. Prof. Ragnhild A. Lothe will lead the Centre together with the interdisciplinary PI team consisting of Prof. Michael Bretthauer (gastroenterologist), Prof. Arild Nesbakken (surgeon), Prof. Kjell Tveit (oncologist) and ass. Prof. Rolf I. Skotheim (bioinformatician).
This is the only Jebsen Centre in Oslo that has Oslo University Hospital as its main host institution. Prof. Sigbjørn Smeland, head of the hosting Division of Cancer, Surgery and Transplantation, said in his talk that the Centre was an excellent example of how to organise and succeed in translational research within a Comprehensive Cancer Centre.
Oct 20, 2014
Oct 10, 2014
Inst. for Cancer Research
Poly(sebacic anhydride) nanocapsules as carriers: effects of preparation parameters on properties and release of doxorubicin
J Microencapsul, 1-9 (in press)
Journal Impact Factor > 5, first or last author from the Institute for Cancer Research
The multitude of molecular analyses in cancer: the opening of Pandora's box
Genome Biol, 15 (9), 447 (in press)
DNA Methylation status of key cell cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors
Clin Cancer Res (in press)